Insights by Type
The combination vaccine segment accounted the largest market share over around 67% in 2023. Hepatitis B is a component of several combination vaccinations that have been created and put on the market. These vaccines offer hepatitis B protection along with defence against other illnesses such hepatitis A, diphtheria, tetanus, pertussis, polio, or Haemophilus influenzae type b (Hib). Combination vaccines increase immunisation rates by providing defence against many illnesses in a single shot. This is crucial in areas with weaker healthcare infrastructure or when treating prevalent diseases requires several immunisations. The hepatitis B market's combination vaccination sector has experienced consistent growth. Pharmaceutical firms have kept up their investments in the creation of fresh combo vaccinations that include hepatitis B defence.
Insights by End Use
The hospitals segment is anticipated to reach USD 4.14 billion, By 2033. The prevalence and incidence of hepatitis B in a specific area or nation have a big impact on how big the market is. Increased hepatitis B infection rates can result in a rise in the need for hospital healthcare services, antiviral drugs, and diagnostic testing. Government-sponsored vaccination campaigns may help to lower hepatitis B cases, which will have an impact on the market. Hospitals may experience a decline in the need for medical services but an increase in the need for vaccinations. The hepatitis B market's treatment segment may develop as a result of the availability of potent antiviral drugs and therapies. Hospital procedures and patient outcomes may be affected by the introduction of new drugs and improvements in treatment plans.
Major players in the market